bioRxiv Science⌕ Search

bioRxiv · 10.1101/667873

RATIONAL DECISION ON THE USE OF ANTIBIOTICS DURING THE DRY PERIOD IN DAIRY COWS

Abstract

The aim of this study was to evaluate the use of antibiotics in cows during the dry period. The survey was performed on 148 teats during the dry period, with sample collection in the period D-70 (70 days before delivery) and D14 (14 days after delivery). The milk samples were collected for the Strip Cup Test (SCT), California Mastitis Test (CMT), Microbiological Culture, Somatic Cell Count (SCC), Somatic Cell Score (SCS) and Hyperkeratosis (HK). The groups in which there were no microorganisms grow were divided into two groups, in the first group only the internal sealant in the teat was used (Group 1) and there was another group with the intramammary antibiotic use associated with the internal sealant (Group 2). Teats which were considered positive, with microbiological growth, were treated with the intramammary antibiotic associated with the internal sealant (Group 3). In the comparison of the results of the CMT test between D-70 and D14, a statistical difference was observed in Groups 2 and 3. Group 3, which comprises the positive teats in D-70 presented a reduction of 83.87% and 32.26% in the CMT test between D-70 and D14. Regarding HK, group 1 and 2 had a statistical difference in relation to group 3 in D-70 and D14. As for the numbers of bacteria isolated in D-70 and D14, there was no difference comparing Group 1 and Group 2, unlike Group 3, which had a difference. Group 1 and Group 2 were all negative teats in D-70, showing that the intramammary antibiotic did not influence the outcome of D14. In group 3 there was a reduction of isolates from 62 to 15 in D14. The most prevalent microorganism was Streptococcus agalactiae with 43.37% of the total isolates, followed by Staphylococcus aureus (16.87%) and Corynebacterium spp. (13.25%) and Coagulase negative Staphylococcus (SCN) (10.84%). The selective treatment of teats in dry dairy cows has advantages over Blanket Dry Cow Therapy by reducing the indiscriminate use of antibiotics, avoiding bacterial resistance, ensuring better milk quality and greater food safety. Antibiotics should only be used for teats with subclinical mastitis, with the microbiological culture at the end of lactation performed by fourth individual mammary.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

LOPES, L., LIMA, A.. 2019-06-11. RATIONAL DECISION ON THE USE OF ANTIBIOTICS DURING THE DRY PERIOD IN DAIRY COWS. https://doi.org/10.1101/667873

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid nanoparticle-encapsulated mRNA encoding CagW, a conserved component of the Helicobacter pylori type IV secretion system, protects mice against H. pylori challenge

Background: Roughly one person in two carries Helicobacter pylori, a pathogen classified by the World Health Organization as a group I carcinogen, and the steady loss of antibiotic efficacy has made prophylaxis an urgent rather than an optional goal. No mRNA vaccine against this organism has yet been tested in the clinic, and CagW, a conserved inner-membrane subunit of the H. pylori type IV secretion system (T4SS), has never been evaluated as an mRNA-encoded antigen. Methods: A codon-optimised construct carrying a signal peptide, the CagW coding sequence and a human IgG Fc tag was synthesised, transcribed into mRNA, encapsulated in lipid nanoparticles (LNPs) and shown to direct antigen expression in HEK293T cells. C57BL/6 mice received three intramuscular doses of CagW-Fc mRNA-LNPs (5 ug mRNA each) at 14-day intervals; animals given alum alone, luciferase mRNA-LNPs or CagW protein adsorbed to alum served as comparators. Humoral readouts (IgG, IgG1, IgG2a, IgM, IgA and secretory IgA), lymphocyte proliferation, CD4+/CD8+ subsets, intracellular IFN-{gamma}, IL-4 and IL-17A and circulating cytokines were quantified before challenge, and protection was assessed after live challenge. Results: The formulation (93.2 nm; PDI 0.13; approximately 90% encapsulation) produced CagW-specific protein in vitro. Vaccination raised high-titre CagW-specific IgG (maximal on day 42), IgM and mucosal sIgA, and drove Th1/Th2-type cellular activation (IL-2, IL-4, IL-12, IFN-{gamma} and IL-17A). After challenge, immunised animals carried markedly fewer gastric bacteria and showed lower urease activity than controls. Conclusions: CagW-Fc mRNA-LNPs are therefore a credible mRNA vaccine platform for H. pylori and warrant further preclinical development.

microbiology↗

Experimental evolution reveals temporally opposing roles for Csu pili during Acinetobacter baumannii respiratory infection

Multidrug-resistant (MDR) Acinetobacter baumannii is an opportunistic pathogen responsible for a wide range of infections, including ventilator-associated pneumonia, bloodstream infections, and urinary tract infections. Most studies investigating A. baumannii pulmonary pathogenesis rely on acute pneumonia models that use high bacterial inocula and do not recapitulate the prolonged infections observed in some patients. Recently, our laboratory developed a murine model of chronic pulmonary infection that enabled the identification of virulence factors specifically required for long-term lung persistence. To investigate how A. baumannii adapts during chronic pulmonary infection, we performed an experimental evolution study using this model. This approach revealed an unexpected role for the archaic chaperone-usher (Csu) pili in A. baumannii pathogenesis. At early time points, Csu expression reduced bacterial burdens in both acute and chronic pneumonia models, an effect associated with enhanced host inflammatory responses. In contrast, at later stages of chronic infection, Csu promoted bacterial persistence, potentially by facilitating adhesion to pulmonary epithelial cells. These opposing effects were conserved across two distinct A. baumannii clinical isolates. We also found that Csu contributes to bacterial colonization in a catheter-associated urinary tract infection (CAUTI) model in a strain-dependent manner. Together, these findings reveal an infection-stage-dependent role for Csu in A. baumannii pathogenesis, demonstrating that a bacterial surface structure can impair early colonization while promoting long-term persistence.

microbiology↗

A Vma13-targeted thiadiazole-succinimide disrupts V-ATPase dependent arginine-polyamine homeostasis to block Candida albicans escape from macrophages

Invasive candidiasis caused by Candida albicans is a life-threatening nosocomial infection with limited therapies and high morbidity and mortality among immunocompromised patients. Within host phagocytes, C. albicans catabolizes arginine to produce ammonia and fuels polyamine biosynthesis, which correlates with phagosomal alkalinization and yeast-to-hypha morphogenesis, facilitating macrophage escape and systemic dissemination. However, new antifungal strategies blocking this fungal escape remain scarce. Here, we characterize the thiadiazole-succinimide derivative ETSI, an arginine-dependent antifungal small molecule with minimal direct growth inhibition under arginine-free conditions yet robust anti-C. albicans activity in arginine-rich microenvironments mimicking the macrophage intracellular niche. Mechanistically, ETSI targets the vacuolar Vma13 to inhibit vacuolar H-ATPase (V-ATPase), dissipating vacuolar proton (H+) gradients and leading to cytoplasmic H+ retention. The accumulated cytoplasmic H+ traps intracellular ammonia and blocks its external release, while impaired vacuolar metabolite sequestration further triggers cytotoxic accumulation of arginine and polyamine metabolites. This dual metabolic perturbation suppresses phagosomal alkalinization, retains C. albicans in yeast form and blocks macrophage escape. ETSI is the first small molecule blocking C. albicans escape via disrupted Vma13/V-ATPase dependent arginine-polyamine homeostasis. This work identifies an intracellular metabolic vulnerability and establishes a niche-targeted antifungal strategy distinct from classic growth-suppressive drugs for treating invasive candidiasis.

microbiology↗